What's new? Log in Free sign up

Qiagen (QGEN)

Company Profile

Company profile

Ticker

QGEN

Exchange

Website

CEO

Mr. Thierry Bernard

Incorporated

Location

Fiscal year end

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • Gilead Sciences • Biogen • Sterling Check • Moderna • Bio-Techne • Acorda Therapeutics • Mach Natural Resources • Saratoga Investment Corp 6.00% ...

Former names

QIAGEN NV

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

QGEN stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

QIAGEN delivers solid performance and exceeds outlook for Q2 2024

Notice of the Annual General Meeting of Shareholders

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

WELLINGTON MANAGEMENT GROUP LLP

BlackRock, Inc.

BlackRock, Inc.

Notice of proposed sale of securities

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

Notice of proposed sale of securities

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

Financial summary

Financial statements Chart QGEN financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Qiagen earnings reports.

Institutional ownership, Q3 2024

QGEN institutional ownership history Ownership history

67.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	322	299	+7.7%
Opened positions	55	72	-23.6%
Closed positions	32	38	-15.8%
Increased positions	124	109	+13.8%
Reduced positions	105	82	+28.0%

13F shares	Current	Prev Q	Change
Total value	6.34 tn	5.82 tn	+9.0%
Total shares	150.65 mm	150.44 mm	+0.1%
Total puts	852.64 k	500.81 k	+70.3%
Total calls	1.41 mm	1.06 mm	+33.2%
Total put/call ratio	0.6	0.5	+27.8%

Largest owners	Shares	Value	Change
Massachusetts Financial Services	23.12 mm	$1.05 tn	-0.3%
Wellington Management	21.25 mm	$963.39 bn	+77.7%
Vanguard	8.80 mm	$397.96 bn	-0.6%
Amundi	5.85 mm	$254.88 bn	-1.5%
BlackRock	5.45 mm	$248.40 bn	NEW
Nuance Investments	4.49 mm	$204.74 bn	-14.8%
BAC Bank of America	4.27 mm	$194.59 bn	+24.6%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	4.16 mm	$187.76 bn	+2.8%
Earnest Partners	3.94 mm	$179.45 bn	+3.4%
MS Morgan Stanley	3.23 mm	$147.38 bn	-6.0%

Largest transactions	Shares	Bought/sold	Change
Wellington Management	21.25 mm	+9.29 mm	+77.7%
BLK BlackRock	0.00	-7.63 mm	EXIT
BlackRock	5.45 mm	+5.45 mm	NEW
Capital International Investors	2.42 mm	-5.03 mm	-67.5%
Norges Bank	0.00	-4.19 mm	EXIT
Millennium Management	1.32 mm	-1.71 mm	-56.4%
BCS Barclays	1.85 mm	+1.17 mm	+170.6%
Point72 Asset Management	46.44 k	-1.14 mm	-96.1%
C Citigroup	409.69 k	-1.03 mm	-71.6%
Victory Capital Management	2.57 mm	+991.33 k	+62.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Qiagen Announces $300M Capital Return Via Synthetic Share Repurchase By January 2025; Follows $300M Returned In Early 2024, Aiming For $1B Total By 2028. Plan Involves 3% Reduction In Issued Shares, Enhancing EPS

Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPSReturn of approximately $300 million – maximum

Qiagen Said Sunday, It Will Return ~$300M To Shareholders Through A Synthetic Share Repurchase

QIAGEN has decided to implement the maximum USD300 million value of the mandate given at the Annual General Meeting in June 2024, where shareholders gave virtually unanimous approval for the related resolutions. This

QIAGEN Enhances QIAcuity Digital PCR With High-Order Multiplexing For Simultaneous Detection Of Up To12 Targets

QIAcuity digital PCR now offers ability for simultaneous detection of up to 12 targets from one biological sample, a more than two-fold increase from prior capability for up to five targetsNo instrument hardware changes

Reported Earlier, QIAGEN Gains FDA Clearance For QIAstat-Dx Mini Gastrointestinal Panel, Supporting Year-Round Outpatient Care

Morgan Stanley Downgrades Qiagen to Equal-Weight, Lowers Price Target to $48

Press releases

From Benzinga Pro

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million

Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS Return of approximately $300 million –

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024. Press release date / time: Wednesday, February 5, shortly after 22:05 Frankfurt time / 21:05

QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS Return of up to $300 million – maximum

QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples

QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.